Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...

Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these ...

Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees ...

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

The Dow Jones Industrial Average lost 696.75 points, or 1.63%, to close at 41,938.45. The S&P 500 slid 1.54% to 5,827.04, ...

The diagnosed prevalent cases of human immunodeficiency virus (HIV) are projected to increase globally at an annual growth r ...

Technology is advancing at a rapid pace, transforming all areas of our lives and leaving barely any aspect of it unimpacted.  This is not a new phenomenon by any degree. Many centuries ago, the ...

Former Tesla board member Antonio Gracias offers to rescue Lykos Therapeutics with $100M deal to save its psychedelic drug ...

Our medical tools and techniques are rapidly improving but our system for delivering health care is a source of widespread ...